Cargando…

Development and external validation of a nomogram for individualized adjuvant imatinib duration for high‐risk gastrointestinal stromal tumors: A multicenter retrospective cohort study

INTRODUCTION: The main emphasis of the research about adjuvant imatinib for high‐risk gastrointestinal stromal tumors (GISTs) is prolonging the treatment duration and ignores the heterogeneous that 10‐year recurrence rates ranged from about 20%–100%. Thus, this study evaluated the effect of differen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ruolin, Wu, Yingxin, Gong, Jin, Zhao, Rui, Li, Li, Wan, Qianyi, Lian, Nan, Shen, Xiaoding, Xia, Lin, Shen, Yuhou, Xiao, Haitao, Wu, Xiaoting, Chen, Yi, Cen, Ying, Xu, Xuewen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385591/ https://www.ncbi.nlm.nih.gov/pubmed/35297216 http://dx.doi.org/10.1002/cam4.4673

Ejemplares similares

Postoperative Adjuvant Imatinib Therapy-Associated Nomogram to Predict Overall Survival of Gastrointestinal Stromal Tumor
por: Liu, Xuechao, et al.
Publicado: (2022)

Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
por: Zhao, Rui, et al.
Publicado: (2017)

CT‐determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia
por: Wan, Qianyi, et al.
Publicado: (2022)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis
por: Liu, Ruolin, et al.
Publicado: (2021)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023)

What is the appropriate duration of adjuvant imatinib mesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture?
por: Lu, Jun, et al.
Publicado: (2019)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Low Skeletal Muscle Mass and the Incidence of Delirium in Hospitalized Older Patients: A Systematic Review and Meta-Analysis of Observational Studies
por: Shen, Yuhou, et al.
Publicado: (2023)

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014)

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
por: Wang, Shang-Yu, et al.
Publicado: (2019)

Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review
por: Shen, Haixiang, et al.
Publicado: (2019)

Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
por: Fulgenzi, Claudia Angela Maria, et al.
Publicado: (2022)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Long-term Results of Adjuvant Imatinib Treatment for Localized Gastrointestinal Stromal Tumors after Surgery
por: Aznab, Mozaffar, et al.
Publicado: (2018)

Sarcopenia and adverse health‐related outcomes: An umbrella review of meta‐analyses of observational studies
por: Xia, Lin, et al.
Publicado: (2020)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Risk factors associated with the progression from keloids to severe keloids
por: Liu, Ruolin, et al.
Publicado: (2022)

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007)

Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis
por: Jiang, Xuehui, et al.
Publicado: (2023)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report
por: Tjhoi, Welda E.H., et al.
Publicado: (2019)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014)

Expression of stem cell factor in gastrointestinal stromal tumors: Implications for proliferation and imatinib resistance
por: HOU, XIAO-WEI, et al.
Publicado: (2013)

Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report
por: Jiang, Meng-jie, et al.
Publicado: (2015)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients
por: Bümming, P, et al.
Publicado: (2003)

Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib
por: Gao, Xiaodong, et al.
Publicado: (2016)

RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor
por: Gao, Xiaodong, et al.
Publicado: (2016)

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor
por: Wang, Gang, et al.
Publicado: (2021)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report
por: Kang, Yoon-Koo
Publicado: (2011)

Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors: Recommendations for Patient Selection, Risk Assessment, and Molecular Response Monitoring
por: Rutkowski, Piotr, et al.
Publicado: (2013)

Budgetary Impact of Treatment with Adjuvant Imatinib for 1 Year Following Surgical Resection of Kit-Positive Localized Gastrointestinal Stromal Tumors
por: Rubin, Jamie L., et al.
Publicado: (2010)

Development and external validation of a simple nomogram for predicting apnea in children hospitalized with bronchiolitis
por: Xu, Qiuyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sohmjfku4hn9ke8sp078oic45u